Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GH35
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GH35 is an investigational small molecule drug administered in tablet form. It is currently being evaluated in clinical trials for its safety and tolerability in patients with advanced solid tumors that harbor a KRAS G12C mutation. The primary objective of these studies is to determine the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D). The drug is designed to target the specific KRAS G12C mutation, aiming to inhibit its oncogenic activity in cancer cells.
- Other names
- GH-KRAS
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on GH35.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GH35.